Related Experiment Videos
Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells
H Juhl1, E C Petrella, N K Cheung
1Department of Biochemistry and Molecular Biology, Georgetown University, Washington, DC, USA.
Abstract:
Insufficient numbers of antigen molecules and heterogeneity of antigen expression on tumor cells are major factors limiting the immunotherapeutic potential of the few clinically useful monoclonal antibodies capable of mediating complement cytotoxicity and antibody-dependent cellular cytotoxicity. To overcome this limitation, we converted two non-cytotoxic monoclonal anti-neuroblastoma antibodies, designated 3E7 (IgG2b) and 8H9 (IgG1), and the non-cytotoxic F(ab')2 fragment of the cytotoxic monoclonal anti-GD2 antibody 3F8 (IgG3) into cytotoxic antibody conjugates by covalent attachment of cobra venom factor (CVF), a structural and functional homologue of the activated third component of complement. Competitive binding experiments confirmed the different specificities of the three antibodies. In the presence of human complement, all three antibody-CVF conjugates mediated selective complement-dependent lysis of human neuroblastoma cells. Consistent with the kinetics of the alternative pathway of complement, approximately seven hours incubation were required to reach maximum cytotoxicity of up to 25% for the 3E7-CVF conjugate, up to 60% for the 8H9-CVF conjugate, and up to 95% for the 3F8 F(ab')2-CVF conjugate. The different extent of maximal cytotoxic activity of the three conjugates was reflected by corresponding differences in the extent of binding of both unconjugated antibodies and the respective conjugates. Any combination of the three antibody-CVF conjugates caused an additive effect in complement-mediated lysis. Using a cocktail of all three conjugates, the extent of complement-mediated killing could be increased up to 100%. These data demonstrate that by coupling of CVF the relative large number of non-cytotoxic monoclonal anti-tumor antibodies of interesting specificity can be used to design cocktails of cytotoxic conjugates and, thereby, to overcome the problem of insufficient and heterogeneous antigen expression on tumor cells for immunotherapy.
Insights
This study developed novel antibody-cobra venom factor (CVF) conjugates to enhance cancer immunotherapy. Combining these conjugates effectively targets tumor cells, overcoming antigen variability for improved complement-dependent cytotoxicity.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Limited efficacy of current immunotherapies due to insufficient tumor antigen expression.
- Monoclonal antibodies (mAbs) show potential but often lack inherent cytotoxic activity.
- Heterogeneity of antigen expression on tumor cells hinders targeted therapies.
Purpose of the Study:
- To engineer cytotoxic antibody conjugates for enhanced neuroblastoma immunotherapy.
- To overcome limitations of insufficient and heterogeneous antigen expression on tumor cells.
- To develop novel therapeutic strategies using antibody-complement factor conjugates.
Main Methods:
- Covalent attachment of cobra venom factor (CVF) to non-cytotoxic anti-neuroblastoma antibodies (3E7, 8H9) and an anti-GD2 antibody fragment (3F8 F(ab')2).
- Assessment of antibody specificities using competitive binding assays.
- Evaluation of complement-dependent cytotoxicity (CDC) against human neuroblastoma cells in vitro.
- Analysis of additive effects of antibody-CVF conjugate cocktails.
Main Results:
- All three antibody-CVF conjugates (3E7-CVF, 8H9-CVF, 3F8 F(ab')2-CVF) demonstrated selective complement-dependent lysis of neuroblastoma cells.
- Cytotoxicity varied, with 3F8 F(ab')2-CVF achieving up to 95% lysis.
- Combinations of conjugates showed additive effects, with a cocktail achieving up to 100% cell killing.
- Conjugate efficacy correlated with antibody binding extent.
Conclusions:
- Coupling cobra venom factor (CVF) to monoclonal antibodies transforms non-cytotoxic antibodies into potent cytotoxic agents.
- Antibody-CVF conjugate cocktails can overcome challenges of insufficient and heterogeneous antigen expression in cancer immunotherapy.
- This approach offers a versatile strategy for developing novel immunotherapeutic agents against various cancers.